These novel therapies , Retatrutide, represent a groundbreaking advancement in managing obesity and potentially associated disorders. These drugs are classified as GLP-1 receptor stimulators, signifying they function to replicate the natural GLP-1 substance , boosting glucose production and reducing food intake. Despite Semaglutide each one operate